APASL 2025 Live: Hepa Thera Presents New Progress in Functional Cure of Hepatitis B

From March 26th to 30th, 2025, Hepa Thera was invited to participate in the 34th Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2025 BEIJING). With two core drug R & D achievements in the field of hepatitis B treatment, the company successfully obtained the qualifications for poster presentation and oral report, and had extensive exchanges with international industry KOL leaders and domestic and overseas partners.

The data from the Ib and extended phase studies of HT-101 (GalNAc-siRNA) released by Hepa Thera show that in the high-dose group of chronic hepatitis B patients, after two administrations, the average maximum decline of hepatitis B surface antigen (HBsAg) exceeded 3.3Log, and the average decline still remained at 2.3 Log at 48 weeks. One patient achieved HBsAg clearance at 48 weeks, which is significantly superior to similar therapies. The concurrently presented 1b data of HT-102 (neutralizing antibody) indicate that in the vast majority of patients, HBsAg declined rapidly after two days of administration, with a decline of more than 2 Log. At the same time, in the medium and high-dose groups, HBsAg still remained at a low level (<10IU/ml) 70 days after administration. Preclinical studies have confirmed that the combination of HT-102 and HT-101 can synergistically inhibit the virus, providing a new strategy for the functional cure of hepatitis B. More latest clinical data will be disclosed in April. Stay tuned.